Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 341

1.

Clinical outcomes with canagliflozin according to baseline body mass index: results from post hoc analyses of the CANVAS Program.

Ohkuma T, Van Gaal L, Shaw W, Mahaffey KW, de Zeeuw D, Matthews DR, Perkovic V, Neal B.

Diabetes Obes Metab. 2019 Nov 14. doi: 10.1111/dom.13920. [Epub ahead of print]

PMID:
31729107
2.

Do GLP-1 Receptor Agonists Care if You Have Heart Failure?

Arnott C, Neal B.

Circulation. 2019 Nov 12;140(20):1623-1625. doi: 10.1161/CIRCULATIONAHA.119.043303. Epub 2019 Nov 11. No abstract available.

PMID:
31710527
3.

Evaluating the Effects of Canagliflozin on Cardiovascular and Renal Events in Patients with Type 2 Diabetes and Chronic Kidney Disease According to Baseline HbA1c, Including Those with HbA1c <7%: Results From the CREDENCE Trial.

Cannon CP, Perkovic V, Agarwal R, Baldassarre J, Bakris G, Charytan DM, de Zeeuw D, Edwards R, Greene T, Heerspink HJL, Jardine MJ, Levin A, Li JW, Neal B, Pollock C, Wheeler DC, Zhang H, Zinman B, Mahaffey KW.

Circulation. 2019 Nov 11. doi: 10.1161/CIRCULATIONAHA.119.044359. [Epub ahead of print]

PMID:
31707795
4.

Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes.

Li J, Woodward M, Perkovic V, Figtree GA, Heerspink HJL, Mahaffey KW, de Zeeuw D, Vercruysse F, Shaw W, Matthews DR, Neal B.

JACC Heart Fail. 2019 Oct 23. pii: S2213-1779(19)30677-8. doi: 10.1016/j.jchf.2019.08.004. [Epub ahead of print]

5.

Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Li Q, Jardine M, Oh R, Heerspink HL, Perkovic V.

J Am Soc Nephrol. 2019 Nov;30(11):2229-2242. doi: 10.1681/ASN.2019010064. Epub 2019 Sep 17.

6.

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.

Neuen BL, Young T, Heerspink HJL, Neal B, Perkovic V, Billot L, Mahaffey KW, Charytan DM, Wheeler DC, Arnott C, Bompoint S, Levin A, Jardine MJ.

Lancet Diabetes Endocrinol. 2019 Nov;7(11):845-854. doi: 10.1016/S2213-8587(19)30256-6. Epub 2019 Sep 5. Erratum in: Lancet Diabetes Endocrinol. 2019 Dec;7(12):e23.

PMID:
31495651
7.

Effects of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes in women versus men.

Rådholm K, Zhou Z, Clemens K, Neal B, Woodward M.

Diabetes Obes Metab. 2019 Sep 4. doi: 10.1111/dom.13876. [Epub ahead of print]

PMID:
31486272
8.

Clinical characteristics, antihypertensive medication use and blood pressure control among patients with treatment-resistant hypertension: the Survey of PatIents with treatment ResIstant hyperTension study.

Carcel C, Neal B, Oparil S, Rogers K, Narkiewicz K, Wang JG, Schiffrin EL, Poulter N, Azizi M, Chalmers J.

J Hypertens. 2019 Nov;37(11):2216-2224. doi: 10.1097/HJH.0000000000002184.

PMID:
31415307
9.

Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.

Zhou Z, Jardine M, Perkovic V, Matthews DR, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Oh R, Simpson R, Watts NB, Neal B.

Diabetologia. 2019 Oct;62(10):1854-1867. doi: 10.1007/s00125-019-4955-5. Epub 2019 Aug 10.

10.

The Healthfulness of the US Packaged Food and Beverage Supply: A Cross-Sectional Study.

Baldridge AS, Huffman MD, Taylor F, Xavier D, Bright B, Van Horn LV, Neal B, Dunford E.

Nutrients. 2019 Jul 24;11(8). pii: E1704. doi: 10.3390/nu11081704.

11.

A comparison of the healthiness of packaged foods and beverages from 12 countries using the Health Star Rating nutrient profiling system, 2013-2018.

Dunford EK, Ni Mhurchu C, Huang L, Vandevijvere S, Swinburn B, Pravst I, Tolentino-Mayo L, Reyes M, L'Abbé M, Neal BC.

Obes Rev. 2019 Nov;20 Suppl 2:107-115. doi: 10.1111/obr.12879. Epub 2019 Jul 22.

PMID:
31328385
12.

Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups.

Mahaffey KW, Jardine MJ, Bompoint S, Cannon CP, Neal B, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Capuano G, de Zeeuw D, Greene T, Levin A, Pollock C, Sun T, Wheeler DC, Yavin Y, Zhang H, Zinman B, Rosenthal N, Brenner BM, Perkovic V.

Circulation. 2019 Aug 27;140(9):739-750. doi: 10.1161/CIRCULATIONAHA.119.042007. Epub 2019 Jul 11.

13.

The performance and potential of the Australasian Health Star Rating system: a four-year review using the RE-AIM framework.

Jones A, Thow AM, Ni Mhurchu C, Sacks G, Neal B.

Aust N Z J Public Health. 2019 Aug;43(4):355-365. doi: 10.1111/1753-6405.12908. Epub 2019 May 29. Review.

14.

The International Consortium for Quality Research on Dietary Sodium/Salt (TRUE) position statement on the use of 24-hour, spot, and short duration (<24 hours) timed urine collections to assess dietary sodium intake.

Campbell NRC, He FJ, Tan M, Cappuccio FP, Neal B, Woodward M, Cogswell ME, McLean R, Arcand J, MacGregor G, Whelton P, Jula A, L'Abbe MR, Cobb LK, Lackland DT.

J Clin Hypertens (Greenwich). 2019 Jun;21(6):700-709. doi: 10.1111/jch.13551. Epub 2019 May 14.

15.

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, Edwards R, Agarwal R, Bakris G, Bull S, Cannon CP, Capuano G, Chu PL, de Zeeuw D, Greene T, Levin A, Pollock C, Wheeler DC, Yavin Y, Zhang H, Zinman B, Meininger G, Brenner BM, Mahaffey KW; CREDENCE Trial Investigators.

N Engl J Med. 2019 Jun 13;380(24):2295-2306. doi: 10.1056/NEJMoa1811744. Epub 2019 Apr 14.

16.

Effects of Canagliflozin on Heart Failure Outcomes Associated With Preserved and Reduced Ejection Fraction in Type 2 Diabetes Mellitus.

Figtree GA, Rådholm K, Barrett TD, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Matthews DR, Shaw W, Neal B.

Circulation. 2019 May 28;139(22):2591-2593. doi: 10.1161/CIRCULATIONAHA.119.040057. Epub 2019 Mar 17. No abstract available.

17.

Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program.

Matthews DR, Li Q, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Desai M, Hiatt WR, Nehler M, Fabbrini E, Kavalam M, Lee M, Neal B.

Diabetologia. 2019 Jun;62(6):926-938. doi: 10.1007/s00125-019-4839-8. Epub 2019 Mar 12.

18.

Sources of Dietary Salt in North and South India Estimated from 24 Hour Dietary Recall.

Johnson C, Santos JA, Sparks E, Raj TS, Mohan S, Garg V, Rogers K, Maulik PK, Prabhakaran D, Neal B, Webster J.

Nutrients. 2019 Feb 1;11(2). pii: E318. doi: 10.3390/nu11020318.

19.

Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.

Toyama T, Neuen BL, Jun M, Ohkuma T, Neal B, Jardine MJ, Heerspink HL, Wong MG, Ninomiya T, Wada T, Perkovic V.

Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.

PMID:
30697905
20.

Estimating the health benefits and cost-savings of a cap on the size of single serve sugar-sweetened beverages.

Cleghorn C, Blakely T, Mhurchu CN, Wilson N, Neal B, Eyles H.

Prev Med. 2019 Mar;120:150-156. doi: 10.1016/j.ypmed.2019.01.009. Epub 2019 Jan 18.

PMID:
30660706

Supplemental Content

Loading ...
Support Center